Background
and Objectives: analogues
insulin is similar to human insulin but have differences in cell structure that
leading to differences in characteristics of pharmacodynamics and
pharmacokinetics.
Methods: A systematic review of published
studies between 2009 until June 2010 in Cochrane Library (CENTRAL and Cochrane
Systematic Reviews), DARE, NHS EEDs, and CRD databases were searched.
Results: Only nine articles were identified
to be included in this review. Most of these studies demonstrated that there
were no more or less risks caused by rapid acting insulin compared with human
insulin in terms of safety. The risk of sever hypoglycemia significantly,
reduced by using long acting insulin analogue. Although it has been shown that
insulin analogues are not cost effective, some of these studies pointed out
that that insulin Aspart 30 compared with other analogues has more cost
effectiveness.
Conclusion: Although
this type of insulin seems very effective for patients with diabetes, due to
the less cost effectiveness in comparison to human insulin, it is recommended
that government's resources for this technology will be allocated just to the
children and elderly people.
Normal 0
Rights and permissions | |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |